Hetero Research Foundation

Hetero Drugs Limited

Kesireddy Subash Chander Reddy

Bandi Parthasaradhi Reddy

Kura Rathnakar Reddy

Dasari Muralidhara Reddy

Rapolu Raji Reddy

Bandi Vamsi Krishna

Rapolu Raju Reddy

Bandi Vamsi Krishan

The present invention provides a solid dispersion of rufinamide in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.

Rufinamide solid dispersion

Described herein is pure amorphous darunavir, methods of making pure amorphous darunavir and pharmaceutical compositions containing amorphous darunavir and a pharmaceutically acceptable excipient.

Amorphous darunavir

The present invention provides novel solvated forms of darunavir and processes for their preparation. The present invention also provides novel processes for the preparation of darunavir amorphous form and pharmaceutical compositions comprising it. Thus, for example, darunavir 2-methyl-2-butanol solvate was dissolved in methylene dichloride, distilled under vacuum at 45&#xb0; C. to obtain a residue, cyclohexane was added to the residue and stirred for 30 hours at 20 to 25&#xb0; C., and the separated solid was filtered, washed with cyclohexane and dried under vacuum at 50&#xb0; C. for 12 hours to yield darunavir amorphous form.

Polymorphs of darunavir

The present invention provides a novel amorphous solid dispersion of linagliptin in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.

Linagliptin solid dispersion

The present invention provides novel crystalline hydrochloride salt of darunavir, process for its preparation and to pharmaceutical composition comprising it. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it.

Crystalline hydrochloride salt of darunavir

The present invention provides novel salts of raltegravir, processes for their preparation and pharmaceutical compositions comprising them. The present invention also provides crystalline sodium salt of raltegravir, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides a process for the preparation of amorphous sodium salt of raltegravir. The present invention further provides a process for the preparation of raltegravir potassium crystalline form H1.

Salts of raltegravir

The present invention provides novel crystalline forms of maraviroc phosphate, processes for their preparation and pharmaceutical compositions comprising them. The present invention also provides novel process for the preparation of maraviroc amorphous form and pharmaceutical composition comprising it.

Crystalline forms of maraviroc phosphate and process for maraviroc amorphous form

The present invention provides novel polymorphs of raltegravir potassium, processes for their preparation and pharmaceutical compositions comprising them. Thus for example, raltegravir potassium was added to water and stirred for 15 minutes, the solution was filtered on hiflo bed and the bed washed with water, the resulting solution was subjected to freeze drying at &#x2212;180 deg C. for 13 hours to give raltegravir potassium amorphous form.

Polymorphs of raltegravir potassium

The present invention provides a novel crystalline form of atazanavir sulfate, process for its preparation and to pharmaceutical composition containing it. In accordance with the present invention atazanavir sulfate was dissolved in methanol, to the solution was added ethyl acetate, the solid obtained was collected by filtration and dried to give atazanavir sulfate crystalline form H1.

Polymorph of atazanavir sulfate

The invention relates to a process for the preparation of stable lamivudine polymorph form and to a composition comprising thereof.

Process for preparing lamivudine polymorph form

The present invention relates to novel amorphous and crystalline forms of efavirenz, processes for their preparation and pharmaceutical compositions containing them. In accordance with the present invention efavirenz crude is dissolved in acetone at 25&#xb0; C.-30&#xb0; C., the solution is slowly added to water for 30 minutes at 0&#xb0; C.-5&#xb0; C., stirred for 1 hour at the same temperature, the separated solid is filtered, washed with water and dried at 55&#xb0; C.-60&#xb0; C. for 5 hours to give amorphous efavirenz.

Polymorphs of efavirenz

The present invention provides a novel cyclohexane solvate form of lopinavir, and a process for its preparation thereof. The present invention also provides a novel desolvated crystalline form of lopinavir, process for its preparation and to pharmaceutical composition containing it. Thus, for example, lopinavir cyclohexane solvate was heated at 100&#xb0; C. for 10 hours to give lopinavir desolvated crystalline form H1.

Polymorphs of lopinavir

The present invention relates to a process for the preparation of crystalline non-hygroscopic form H1 of efavirenz, and pharmaceutical compositions containing it. In accordance with the present invention efavirenz was dissolved in acetone at 25&#xb0; C.-30&#xb0; C., the solution was slowly added to water at 0&#xb0; C.-5&#xb0; C., the separated solid was filtered, washed with mixture of acetone and water and dried at 25&#xb0; C.-35&#xb0; C. under below 65% relative humidity for 18 hours to give crystalline non-hygroscopic efavirenz form H1.

Growing community of inventors

Hyderabad Telangana, India

Kesireddy Subash Chander Reddy